Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Apixaban 5mg Tablets in Healthy Subjects
NCT06043297Phase 1Completed
- Sponsor
- Humanis
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apixaban in thromboembolism (2 arms), sponsored by Humanis. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration. Started Feb 2023; status: completed.
02
Drugs
apixaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT06043297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06043297.